Can eculizumab be discontinued in aHUS?: Case report and review of the literature

BACKGROUND: The management of atypical hemolytic uremic syndrome (aHUS) has evolved into better control of thrombotic microangiopathy (TMA) and recovery of renal functions since the recent introduction of the terminal complement cascade blocker, eculizumab, into clinical use. Better characterization...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Medicine (Baltimore)
Asıl Yazarlar: Sahutoglu, Tuncay, Basturk, Taner, Sakaci, Tamer, Koc, Yener, Ahbap, Elbis, Sevinc, Mustafa, Kara, Ekrem, Akgol, Cuneyt, Caglayan, Feyza Bayraktar, Unsal, Abdulkadir, Daha, Mohamed R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Wolters Kluwer Health 2016
Konular:
5200
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979790/
https://ncbi.nlm.nih.gov/pubmed/27495036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000004330
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller